natgillin/translations-raw huggingface dataset:
In a further embodiment of the first aspect of the present invention, the above-mentioned compound of formula (5): 
NŽ>NH, o se priprema u sljedećem koraku A5: pri čemu je spoj s formulom (5):
A lower face of the compartment is designed for the release of beverage out of the ingredient compartment under the effect of the pressure building up inside the ingredient compartment. The lower face is permanently opened under the effect of the rise in pressure in the capsule. This pressure is typically caused by the injection of water into the ingredient compartment. 
Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što ventil (15) se nalazi nizvodno od površine (4) odjeljka. Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što ventil (15) je tako osmišljen da omogući protok tek kada tlak u odjeljku (5) bude veći od okolnog tlaka.
receiving (202) incoming laser radiation with a plurality of spatially separated laser detectors, filtering (204) out noise and irrelevant receptions using at least one filtering mechanism (122, 124, 126); and 
filtriranja (204) buke i nevažnih prijema upotrebom najmanje jednog mehanizma za filtriranje (122, 124,126); i pozitivnog identificiranja (212) navedenog izvora prijetnje pomoću najmanje jednog mehanizma za prepoznavanje prijetnje (130, 132), naznačeno time da navedeni mehanizam za filtriranje sadrži:
• the compound is not aromatized by aromatase; 
(11) aromataza ne aromatizira spoj;
The use according to enbodiment 41, wherein the patient being treated has been pre-treated with IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. 
Protutijelo za uporabu prema zahtjevu 24, naznačeno time, da je pacijent koji se liječi, bio podvrgnut predliječenju s IGF-1, IGF-2 ili s varijantama od IGF-1 ili IGF-2, protutijelom anti-miostatin, miostatin-propeptidom, miostatin-decoy-proteinom koji veže ActRIIB, ali ga ne aktivira, beta 2-agonistom, Ghrelin-agonistom, SARM-om, GH-agonistima/mimeticima ili folistatinom.
The security element according to claim 8, characterized in that a plurality of said magnetic (3) areas are sequentially arranged on the substrate (1, 2) so as to be adjacent to each other and/or to be spaced apart from each other by a predetermined space. 
Sigurnosni element prema zahtjevu 8, naznačen time što je više tih magnetskih (3) područja uzastopce razmješteno na supstratu (1, 2) tako da su međusobno susjedni i/ili razmaknuti na određenoj udaljenosti.
Oxidative modification of low-density lipoprotein (LDL) is currently believed to be a central event in the development of atherosclerotic cardiovascular disease. 
Sada se vjeruje da je oksidativna modifikacija lipoproteina niske gustoće (LDL) središnji dogođaj u razvoju aterosklerozne kardiovaskularne bolesti.
represents the C-terminal group of the peptidic compound and is selected from OH and NH2, or a salt or solvate thereof, wherein the compound is a GLP-1 and GIP receptor agonist. 
predstavlja C-terminalnu skupinu peptidnog spoja i odabrana je od OH i NH2, ili njegova sol ili solvat, pri čemu spoj je agonist GLP-1 i GIP receptora.
The aryloazol-2-yl-cyanoethylamine for use according to claim 15 wherein the ectoparasitic infection is with fleas. 
Paraziticidni sastav za uporabu prema zahtjevu 18, naznačen time, da se radi o ektoparazitnim infekcijama koje se prenose s buhama.
A crystalline structure of a compound of formula II which is the (S)-propylene glycol solvate or the (R)-propylene glycol solvate or a mixture thereof, wherein 
Kristalna struktura spoja s formulom II li koja je (S)-propilen glikol solvat ili (R)-propilen glikol solvat ili njihova smjesa, naznačena time da
The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is 
Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj:
A method according to claim 2, wherein nascent H2O2 is removed with the aid of a catalase. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se nastali H2O2 uklanja pomoću katalaze.
The therapeutic hosiery item according to one or more of the preceding claims, characterized in that the count of the elastomer yarn (1a) of said first rows of knitting (1) is comprised between 11.11 and 311.11 dtex. 
Terapeutska čarapa prema jednom ili više prethodnih zahtjeva, naznačena time, da se broj elastomernog konca (1a) spomenutih neparnih redova pletiva (1) nalazi između 11,11 1311,11 deteksa.
A compound for use according to claim 13 wherein said pain is selected from inflammatory pain, centrally mediated pain, peripherally mediated pain, visceral pain, structural related pain, cancer pain, soft tissue injury related pain, progressive disease related pain, neuropathic pain and acute pain from acute injury, acute pain from trauma, acute pain from surgery, chronic pain from headache, chronic pain from neuropathic conditions, chronic pain from post-stroke conditions and chronic pain from migraine. 
Spoj za upotrebu prema patentnom zahtjevu 13 naznačeno time što je navedena bol izabran od inflamatorne boli, centralno posredovane boli, periferno posredovane boli, visceralne boli, boli povezane sa strukturom, boli od karcinoma, boli povezane s povredom mekog tkiva, boli povezane s progresivnom bolešću, neuropatske boli i akutne boli od akutne povrede, akutne boli traume, akutne boli od operacije, kronične boli od glavobolje, kronične boli od neuropatskih stanja, kronične boli od stanja nakon srčanog udara i kronične boli od migrene.
The compound or pharmaceutically acceptable salt thereof according to (1) above, wherein in formula (I), R3 is a phenyl group, a naphthyl group or an isoquinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group D [wherein the group D consists of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, an amino group which may be substituted with one or two C1-C6 alkyl groups, a morpholino group, and a piperazino group which may be substituted with a C1-C6 alkyl group(s)]. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da u formuli (1), R* je fenilna skupina, naftil skupina ili izokinolinil skupina, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine D [pri čemu skupina D sadrži atom halogena, Cy-Cg alkilnu skupinu, C,-Cg alkoksi skupinu, amino skupinu koja može biti supstituirana sa jednom ili dvije C;-Cg alkilne skupine, morfolino skupinu, te piperazino skupinu koja može biti supstituirana sa C;-Cg alkil skupinom(ama)].
The compound according to claim 2, wherein A is an optionally substituted phenylene, an optionally substituted thiophen-di-yl or an optionally substituted pyridin-di-yl. 
Spoj prema zahtjevu 2, naznačen time, da A je opcijski supstituiran fenilen, opcijski supstituiran tiofen-di-il ili opcijski supstituiran piridin-di-il.
a shredding-system assigned to the electric arc furnace for shredding discarded iron and/or steel junk (scrap) is powered uninterruptedly or at least during a melting process cycle by the electric energy generated from the process exhaust (furnace top). 
je dodijeljena elektrolučnoj peći (10) za drobljenje odbačenog željeza i/ili čeličnog otpada (odlomak - = i1pokreće se energijom za vrijeme ciklusa postupka taljenja pomoću električne energije proizvedene iz procesuiranja ispušnih plinova kroz ispušni uređaj (vrh peći 20).
The umbrella as recited in claim 1, wherein the umbrella comprises a compressible material and a valve and through compression of the compressible material, a gaseous substance for inflation can be aspirated via the valve and conveyed into an interior of the inflatable envelope. 
Kišobran kao što je navedeno u patentnom zahtjevu 1, naznačen time da kišobran ima materijal koji se može stlačiti (705) i ventil (710), te se putem kompresije materijala koji se može stlačiti, plinovita tvar za napuhavanje može usisati preko ventila i prenosi se u unutrašnjost omotača za napuhavanje.
In general, oral and parenteral dosages will be in the range of 5 to 400 mg per day of active substance. 
Uopće, oralne i parenteralne doze će biti u opsegu od 5 do 400 mg na dan aktivne supstancije.
in particular the rate of application of Metazachlor is usually 50 to 5000 g/ha, as a rule 75 to 3000 g/ha, preferably 100 to 2000 g/ha, of active substance (a.s.). 
Stopa primjene kloroacetamida - npr., metazaklora, metolaklora, dimetenamida - je obično 50 do 5000 g/ha, kao pravilo 75 do 3000 g/ha, poželjno 100 do 2000 g/ha, aktivne supstance.
Providing milk in liquid form 
Osiguravanje mlijeka u tekućem obliku aii.)
An anti-C5 antibody for use in prolonging survival of a kidney allograft in a recipient mammal, wherein the anti-C5 antibody inhibits cleavage of complement component C5 into fragments C5a and C5b and wherein the anti-C5 antibody is to be administered to the recipient mammal in conjunction with an inhibitor of IL-2 and an immunosuppressive drug that is not associated with significant nephrotoxicity. 
PATENTNI ZAHTJEVI Anti-C5 antitijelo za uporabu u produžavanju preživljavanja bubrežnog transplantata u sisavcu primatelju, naznačeno time, što anti-C5 antitijelo inhibira siječenje C5 komponente komplementa na dijelove C5a i C5b i pri čemu se anti-C5 antitijelo primjenjuje kod sisavca primatelja zajedno sa inhibitorom IL-2 i imunosupresivnim lijekom koji nije udružen sa značajnom nefrotoksičnošću.
1 to 24, which is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 10, naznačen time, da je u obliku praška, granula, tableta ili liofilata/liofilizata.
Preferably the present infant and/or toddler nutrition comprises long chain polyunsaturated fatty acids (LC-PUFA), more preferably eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA), and/or arachidonic acid (ARA). 
Hrana u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što nadalje sadrži eikosapentaensku kiselinu (EPA) i/ili dokozaheksaensku kiselinu (DHA) i/ili arahidonsku kiselinu (ARA).
comprising a reduction of a compound of general formula (IX): 
(ča) naznačen time, da obuhvaća redukciju spoja opće formule (IX): z
Employing an adhesive agent that is activated at a higher temperature the attachment portion 2 can be bonded in position during the laminating stage when the temperature is raised. 
Upotrebom ljepljivog sredstva koje se aktivira kod više temperature, predio za povezivanje 2 može biti povezan u svojem položaju HR P20060169 T3 za vrijeme faze spajanja slojeva, kada se temperatura povisuje.
a VL which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence SEQ ID NO:4, said CDR2' having the amino acid sequence SEQ ID NO:5, and said CDR3' having the amino acid sequence SEQ ID NO:6 wherein the hypervariable regions are according to the Kabat definition. 
VL koji obuhvaća u nizu hipervarijabilna područja CDR1’, CDR2’ i CDR3’, gdje navedeno područje CDR1’ ima aminokiselinsku sekvencu SEQ ID NO:4, navedeno područje CDR2’ ima aminokiselinsku sekvencu SEQ ID NO:5, i navedeno područje CDR3’ ima aminokiselinsku sekvencu SEQ ID NO:6, dok su hipervarijabilna područja određena prema Kabat-definiciji.
The preform according to claim 1, wherein the flange comprises a flange end having a thickness less than 0.3 mm and wherein the flange has a wall thickness that is less than or equal to a cylindrical neck wall thickness. 
Predoblik prema Zahtjevu 1, naznačen time što je debljina (gl) oboda (3) manja od ili jednaka debljini (g2) cilindričnog vrata (2).
A counter as claimed in any one of claims 7 to 10, wherein said third ring member (1502) comprises one or more locating recesses (1508a, 1508b, 1508c) disposed in an upper circumferential surfaces for engaging with correspondingly-shaped protrusions in a housing for preventing free rotation of said third ring member. 
Brojač prema bilo kojem zahtjevu od 1 do 13, naznačeno time da spomenuti treći prstenasti element (1502) sadrži jedan ili više udubljenja za pozicioniranje (1508a), (1508b), (1508c) koji se nalaze na gornjoj površini obujma za djelovanje sa odgovarajuće oblikovanim izbočenjima u kućištu kako bi se onemogućila slobodna rotacija spomenutog trećeg prstenastog elementa.
The compound for use according to claim 5, wherein the second RNA viral polymerase is selected from the group consisting of orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae viral polymerases. 
polimeraza odabrana iz skupine koja se sastoji od virusnih polimeraza orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae; ili
The method of claim 15, wherein said treatment cycle continues for up to 12 months. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, pri čemu se navedeni ciklus liječenja nastavlja do 12 mjeseci.
The method of any one of claims 1-3, wherein the method further comprises contacting the reaction mixture after step b) with an aqueous solution containing bicarbonate or carbonate or contacting the reaction mixture with a metal scavenger. 
Postupak prema bilo kojem od zahtjeva 1-3, naznačen time što postupak dalje sadrži kontaktiranje reakcijske mješavine nakon koraka b) s vodenom otopinom koja sadrži bikarbonat ili karbonat ili kontaktiranje reakcijske mješavine s metalnim čistačem.
and R2 are independently selected from H, benzyl, substituted benzyl, phenyl, substituted phenyl, C1-6alkyl, substituted C1-6alkyl, C3-6cycloalkyl, substituted C3-6cycloalkyl, and heteroaryl, providing that both R1 and R2 are not hydrogen, 
i R2 su neovisno odabrani od H, benzila, supstituiranog benzila, fenila, supstituiranog fenila, C1-6alkila, supstituiranog C1-6alkila, C3-6cikloalkila, supstituiranog C3-6cikloalkila, i heteroaril, pod uvjetom da oba R1 i R2 nisu vodik,
In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control. A method of treating a patient in need of pirfenidone and suffering from a Grade 2 abnormality in a liver function biomarker selected from the group consisting of alanine transaminase (ALT) and aspartate transaminase (AST) and wherein the abnormality occurs after a first pirfenidone administration, comprising providing to said patient a second administration of pirfenidone, comprising (a) administering to said patient at doses of at least 1600 mg/day or 1602 mg/day. 
Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koji je više od 2.5- do 5- puta povećana u usporedbi s gornjom granicom normalnih vrijednosti, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu je davan pirfenidon u dozama od bar 1600 mg/dnevno ili 1602 mg/dnevno.
A further suitable method of removing the acid labile protecting group wherein R1 is a benzyl group in step (k) is by reaction with an acid, such as trifluoroacetic acid. 
Postupak prema zahtjevu 9, naznačen time, da R' je benzil, a u koraku (k) se benzilna skupina odstranjuje pomoću reakcije sa agensom pogodnim za hidrogenizaciju.
A process according to claim 1 wherein the flow rate ratio of the second flowing stream: the first flowing stream is at least 20:1 up to 1000:1. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu je udio protoka drugog tekućeg mlaza: prvi tekući mlaz najmanje 20:1 do 1000:1.
The method of claim 1, wherein R1 is a hydrogen atom and R2 is isobutyl. 
i R* u Formuli 3 i Formuli 8 je definiran kao za Formulu 1;
The basin according to one or more of the preceding claims, characterized in that said first waterproofing layer (15) is provided by means of one or more sheets of EPDM (Ethylene Propylene Diene Monomer) or other similar and equivalent material having such elasticity properties as to allow the underlying ground to shift without causing problems to the waterproofing. 
Osnova sukladno jednom ili više prethodnih zahtjeva, naznačena time što je navedeni prvi vodootporni sloj (15) pružen posredstvom jednog ili više listova EPDM (etilen propilen dien monomer) ili drugog sličnog 1 ekvivalentnog materijala koji ima takve karakteristike elastičnosti da omogućuje tlu ispod pomicanje bez utjecaja na vodootpornost.
a hydrophilic surfactant having an HLB value of at least 8; 
hidrofilni tenzid koji ima HLB-vrijednost od najmanje 8;
A compound of the following formula: 
Spoj sljedeće formule:
The composition or vaccine for use according to any one of claims 1-8, further comprising a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-8, naznačen/o time, da nadalje obuhvaća farmaceutski ili veterinarski prihvatljiv/o nosač, pomoćno sredstvo, prenositelj 1li kemijski dodatak.
The resulting mixture was extracted with diethyl ether (3x200 mL) then the organic layers were combined, washed with brine (100 mL), dried (magnesium sulfate) and the solvent evaporated. 
Dobivenu smjesu ekstrahira se dietil-eterom (3 x 200 ml), organske slojeve se pomiješa, ispere slanom vodom (100 ml), osuši (magnezijev sulfat), a otapalo otpari.
The reaction was diluted with dichloromethane (10ml) and 2N HCl (1 0ml) added. 
Reakcijsku smjesu razrijedi se diklormetanom (10 ml), te se doda 2 N HCI (10 ml).
Frame according to claim 1, wherein said hinging axis is preferably arranged in a transversely inner position of said lateral module (3). 
Okvir u skladu sa patentnim zahtjevom 1, gdje navedena os šarke je poželjno postavljena u transverzalno unutrašnjem položaju navedenog lateralnog modula (3).
wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than about 60% of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates and the non-flattened reference tablet or reference multi particulates provide an in-vitro dissolution rate, which when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C., is between about 5 and about 40% (by wt) active agent released after 0.5 hours. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, pri čemu formulacija matrice s produljenim otpuštanjem nakon što je skladištena pri 25 *€ i 60 % relativne vlažnosti zraka barem 1 mjesec daje stupanj otapanja, kad je mjerena u USP uređaju (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez prisustva enzima (SGF) pri 37 *C, naznačen time da je postotna količina aktivnog agensa oslobođena pri 1, 4 ili 12 sati otapanja koja odstupa ne više od oko 15 % točaka od odgovarajuće in-vitro stupnja otapanja referentne formulacije prije skladištenja.
A crystal solvate according to claim 1 or 2, characterized by a XRPD displaying peaks at diffraction angle 2θ of 3.3 and 19.9 ± 0.1 
Kristalni solvat u skladu s patentnim zahtjevom | ili 2, naznačen time što XRPD ima vršne vrijednosti pri kutu difrakcije 20 od 3,31199 + 0.1 4.
Dissolving or suspending either one or both of a fumaric acid ester and a rate-controlling agent in the form of a polymeric matrix material in water to obtain an aqueous suspension thereof; 
sastavljanje navedenih kristala dimetilfumarata, hidroksipropilceluloze u obliku materijala polimernog matriksa, i bilo kojeg farmaceutski prihvatljivog pomoćnog sredstva i aditiva pomoću izravnog stlačivanja za dobivanje formulacije tablete;
A cement admixture as recited in claim 4, wherein said potentially hydraulic substance and/or said pozzolan substance contain one or two or more selected from the group consisting of finely pulverized, quenched, granulated blast-furnace slag, fly ash, silica fume, metakaolin, incinerated pulp sludge ash, incinerated sewage sludge ash, and waste glass powder. 
Cementna primjesa u skladu s patentnim zahtjevom 3, naznačena time što navedena potencijalno hidraulična tvar i/ili navedena pucolanska tvar sadrže jedan ili dva ili više od onoga što se bira iz skupine koju čine u fini prah mljevena gašena, granulirana troska iz visoke peći, leteći pepeo, koloidni silicijev dioksid, metakaolin, spaljeni pepeo mulja drvenjače, spaljeni pepeo kanalizacijskog mulja, te otpadni stakleni prah.
one or more sources of lithium ions in an amount such that the total amount of lithium ions in the aqueous preparation is from 750 to less than 3000 ppm, calculated relative to the water in the preparation, and 
jednog ili više izvora litijevih iona u količini tako da je ukupna količina litijevih iona u vodenom pripravku od 750 do manje od 3 000 ppm, računato u odnosu na vodu u pripravku, i
Preferred are pharmaceutical forms suitable for the oral administration, such as tablets, capsules, granules, powders, solutions, suspensions, syrups or the like. 
Za upotrebu u terapiji, spojevi iz izuma će biti pogodno formulirani za oralno davanje kao što su tablete, kapsule, granule, prašci, otopine, suspenzije, sirupi i slično.
The human ssAAV vector for use according to any one of the preceding claims, wherein expression of the therapeutic protein in the vector is controlled by an ubiquitous, regulated and/or tissue-specific promoter. 
AAV vektor iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je ekspresija terapijskog proteina kontrolirana sveprisutnim, reguliranim i/ili tkivno-specifičnim promotorom.
This material was purified on the biotage flash 40M column (SiO2) using 30% ethyl acetate-hexanes. 
Dobiveni materijal se pročisti na Biotage Flash 40M koloni (SiO2) uporabom 30% etil acetat/heksan.
and R6 are independently chosen from hydrogen, alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl. 
R" je odabran između vodika, alkila, arila, alkilarila, supstituiranog alkila, supstituiranog arila, i supstituiranog alkilarila.
reaction (N-reac) is a reaction of compound of formula (XXII) with a catalyst (N-cat); 
Pri tome se kod reakcije (N-reak.) radi o reakciji spoja formule (XXII) sa katalizatorom (N-kat.);
A compound of Formula (II) wherein 
Spoj Formule (II) [image], naznačen time što X je CH;
Cytotoxic modular antibody with a molecular weight of up to 60kD, which comprises a CH2 domain and a CH3 domain of a human IgG1 heavy chain and specifically binds to a human receptor of the erbB class with a binding affinity of Kd <10-8 M, wherein the antibody contains a binding site for the receptor of the erbB class within a structural loop region of the CH3 domain of the antibody, and wherein the cytotoxic modular antibody binds to human Fc receptor CD64, FcRn and/or Protein A. 
Citotoksično modularno antitijelo sa molekulskom masom do 60kD, specifično se vezuje za humani Her2 sa afinitetom vezivanja Kd <10-8 M, gdje antitijelo sadrži fragment teškog lanca humanog IgG1 koji sadrži CH2 domenu i CH3 domenu i gdje antitijelo sadrži vezujuće mjesto koje se specifično vezuje za Her2 koji je projektiran u strukturnoj regiji petlje CH3 domena i sadrži amino-kiselinske sekvence sa identifikacijskim brojevima sekvenci (SEQ ID NO) 191, 241 i 370, gdje SEQ ID NO: 191 je sadržana unutar AB petlje, SEQ ID NO: 241 je sadržana unutar CD petlje, i SEQ ID NO: 370 je sadržana unutar EF petlje strukturne regije petlje.
A Compound of formula Q 
Spoj formule Q gdje
the HER3 ligand-independent phosphorylation assay uses HER2 amplified cells, wherein the HER2 amplified cells are SK-Br-3 cells and 
fosforilacijska analiza neovisna o HER3-ligandu, upotrebljava HER2-amplificirane stanice, gdje HER2-amplificirane stanice su SK-Br-3-stanice; i